Marie-Liesse Asselin-Labat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marie-Liesse Asselin-Labat has a total of 424 co-authors. Here are the top co-authors by number of shared publications:
- Claire Marceaux
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
29 shared publications - Clare E. Weeden
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom
18 shared publications - Belinda Phipson
Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
15 shared publications - Adam Pennycuick
UCL Respiratory, University College London, London, UK
14 shared publications - Ayse U. Akarca
Department of Cellular Pathology, University College London Hospitals, London, UK
14 shared publications - Charles Swanton
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
14 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Springer Nature in Cell Death & Differentiation
Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer
Tumour-infiltrating FOXP3 + regulatory T cells (Tregs) exert suppression of anti-tumour immunity in non-small cell lung cancer (NSCLC), contributing to poor prognosis and immunotherapy resistance. The BCL-2 family pro-survival protein, MCL-1, is a critical controller of lymphoid Treg viability, yet its role in tumour-infiltrating Tregs remains poorly defined. Here we find that tumour-infiltrating effector Tregs in human NSCLC exhibit an activation-associated shift in BCL-2 family pro-survival protein expression typified by elevated MCL-1 expression. Pharmacological inhibition of MCL-1 with the BH3 mimetic S63845 induced moderate apoptotic cell death in both human and murine tumour-infiltrating Tregs, coincident with transient enhancement of CD8⁺ T cell activity. Combined MCL-1 inhibition and anti-PD1 immunotherapy further reduced tumour-infiltrating effector Treg abundance and influenced CD8⁺ T cell dynamics, although these effects were not sufficient to extend long-term survival. Mechanistically, we found that IL-33 upregulated MCL-1 expression and was required to support activated tumour-infiltrating Tregs. These results establish MCL-1 as an important regulator for tumour-infiltrating Treg survival and highlight the potential of repurposing BH3 mimetics to modulate immune suppression in NSCLC.
- 15 July 2026
- Published by Springer Nature in Cell Death & Differentiation
Open AccessRepurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer
Tumour-infiltrating FOXP3 + regulatory T cells (Tregs) exert suppression of anti-tumour immunity in non-small cell lung cancer (NSCLC), contributing to poor prognosis and immunotherapy resistance. The BCL-2 family pro-survival protein, MCL-1, is a critical controller of lymphoid Treg viability, yet its role in tumour-infiltrating Tregs remains poorly defined. Here we find that tumour-infiltrating effector Tregs in human NSCLC exhibit an activation-associated shift in BCL-2 family pro-survival protein expression typified by elevated MCL-1 expression. Pharmacological inhibition of MCL-1 with the BH3 mimetic S63845 induced moderate apoptotic cell death in both human and murine tumour-infiltrating Tregs, coincident with transient enhancement of CD8⁺ T cell activity. Combined MCL-1 inhibition and anti-PD1 immunotherapy further reduced tumour-infiltrating effector Treg abundance and influenced CD8⁺ T cell dynamics, although these effects were not sufficient to extend long-term survival. Mechanistically, we found that IL-33 upregulated MCL-1 expression and was required to support activated tumour-infiltrating Tregs. These results establish MCL-1 as an important regulator for tumour-infiltrating Treg survival and highlight the potential of repurposing BH3 mimetics to modulate immune suppression in NSCLC.
- 13 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (11) , 2579-2580
Epigenetic Imprinting Bridges Infection and Lung Cancer
The COVID-19 pandemic has highlighted the long-term impact of viral infections on health, yet the impact of SARS-CoV-2 infection on lung cancer development has remained unclear. In a recent study published in Cell, Qian and colleagues describe an increased risk for the development of lung cancer in patients who suffered from past severe COVID-19. To dissect the mechanisms underlying the epidemiologic evidence, the authors used multiple murine cancer models to demonstrate that respiratory infections, including flu and SARS-CoV-2 infections, remodel the lung tissue microenvironment, leading to an accumulation of neutrophils and immunosuppressive cytokines that promote and sustain a tumor-prone environment. Tumors from previously infected mice contained not only increased numbers of protumorigenic neutrophils but also CD8+ T cells that showed more pronounced signs of immune exhaustion. SARS-CoV-2 vaccination reduced the increase in cancer growth, and blocking neutrophil infiltration combined with immune checkpoint blockade reversed the increase in lung tumor burden. This study demonstrates a long-term molecular memory, or epigenetic imprinting, induced by viral infections in both epithelial and immune cells that can accelerate oncogenesis, and highlights how vaccination protects not only against acute viral infections but also limits the long-term impact of infection on future cancer development.
- 13 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (11) , 2579-2580
Epigenetic Imprinting Bridges Infection and Lung Cancer
The COVID-19 pandemic has highlighted the long-term impact of viral infections on health, yet the impact of SARS-CoV-2 infection on lung cancer development has remained unclear. In a recent study published in Cell, Qian and colleagues describe an increased risk for the development of lung cancer in patients who suffered from past severe COVID-19. To dissect the mechanisms underlying the epidemiologic evidence, the authors used multiple murine cancer models to demonstrate that respiratory infections, including flu and SARS-CoV-2 infections, remodel the lung tissue microenvironment, leading to an accumulation of neutrophils and immunosuppressive cytokines that promote and sustain a tumor-prone environment. Tumors from previously infected mice contained not only increased numbers of protumorigenic neutrophils but also CD8+ T cells that showed more pronounced signs of immune exhaustion. SARS-CoV-2 vaccination reduced the increase in cancer growth, and blocking neutrophil infiltration combined with immune checkpoint blockade reversed the increase in lung tumor burden. This study demonstrates a long-term molecular memory, or epigenetic imprinting, induced by viral infections in both epithelial and immune cells that can accelerate oncogenesis, and highlights how vaccination protects not only against acute viral infections but also limits the long-term impact of infection on future cancer development.
- Open Access
jazzPanda: A hybrid approach to find spatial marker genes in imaging-based spatial transcriptomics data
Spatial transcriptomics enables the understanding of the spatial architecture of tissues, providing deeper insight into tissue structure and cellular neighbourhoods. A crucial step in the analysis of spatial data is cell type identification. In single cell RNA-sequencing (scRNA-seq) analysis, cells are clustered according to their transcriptional similarity, and marker genes for each cluster identified. Marker analysis identifies genes highly expressed in each cluster compared to the remaining clusters, and these marker genes are used to annotate clusters with cell types. For spatial data, there are limited software tools for appropriate marker gene detection methods that account for the spatial distribution of gene expression. Tools developed for scRNA-seq ignore spatial information for the cells and genes. We have developed a hybrid approach to prioritize marker genes that uses the spatial coordinates of gene detections and cells making up clusters. We propose a binning approach that effectively “pseudobulks” gene detections and cells within clusters that can then be used as input into linear models for marker analysis. Our approach can account for multiple samples and background noise. We have tested our methods on several public datasets from different platforms including Xenium, CosMx and MERSCOPE. The marker genes detected by our method show strong spatial correlation with the corresponding clusters and have increased specificity compared to other methods. The method is implemented in the jazzPanda R Bioconductor package and is publicly available ( https://bioconductor.org/packages/jazzPanda ).
Open AccessjazzPanda: A hybrid approach to find spatial marker genes in imaging-based spatial transcriptomics data
Spatial transcriptomics enables the understanding of the spatial architecture of tissues, providing deeper insight into tissue structure and cellular neighbourhoods. A crucial step in the analysis of spatial data is cell type identification. In single cell RNA-sequencing (scRNA-seq) analysis, cells are clustered according to their transcriptional similarity, and marker genes for each cluster identified. Marker analysis identifies genes highly expressed in each cluster compared to the remaining clusters, and these marker genes are used to annotate clusters with cell types. For spatial data, there are limited software tools for appropriate marker gene detection methods that account for the spatial distribution of gene expression. Tools developed for scRNA-seq ignore spatial information for the cells and genes. We have developed a hybrid approach to prioritize marker genes that uses the spatial coordinates of gene detections and cells making up clusters. We propose a binning approach that effectively “pseudobulks” gene detections and cells within clusters that can then be used as input into linear models for marker analysis. Our approach can account for multiple samples and background noise. We have tested our methods on several public datasets from different platforms including Xenium, CosMx and MERSCOPE. The marker genes detected by our method show strong spatial correlation with the corresponding clusters and have increased specificity compared to other methods. The method is implemented in the jazzPanda R Bioconductor package and is publicly available ( https://bioconductor.org/packages/jazzPanda ).
- Open Access
- 9 February 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (2) , 102593
TNF-⍺-mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma
- 9 February 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (2) , 102593
Open AccessTNF-⍺-mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma
- Open Access
- 12 December 2025
- Published by Springer Nature in Research Square
Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer
Tumour-infiltrating FOXP3 + regulatory T cells (Treg) exert suppression of anti-tumour immunity in non-small cell lung cancer (NSCLC), contributing to poor prognosis and immunotherapy resistance. The BCL-2 family pro-survival protein, MCL-1, is a critical controller of lymphoid Treg viability, yet its role in tumour-infiltrating Tregs remains poorly defined. Here we find that tumour-infiltrating effector Tregs in human NSCLC exhibit an activation-associated shift in BCL-2 family pro-survival protein expression typified by elevated MCL-1 expression. Pharmacological inhibition of MCL-1 with the BH3 mimetic S63845 induced moderate apoptotic cell death in both human and murine tumour-infiltrating Tregs, coincident with transient enhancement of CD8⁺ T cell activity, although these effects were not sustained long term. Combined MCL-1 inhibition and anti-PD1 immunotherapy further reduced tumour-infiltrating effector Treg abundance and influenced CD8⁺ T cell dynamics, indicating that targeting MCL-1 can transiently relieve Treg-mediated immunosuppression. These results establish MCL-1 as an important regulator for tumour-infiltrating Treg survival and highlights the potential of repurposing BH3 mimetics to modulate immune suppression in NSCLC.
- 12 December 2025
- Published by Springer Nature in Research Square
Open AccessRepurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer
Tumour-infiltrating FOXP3 + regulatory T cells (Treg) exert suppression of anti-tumour immunity in non-small cell lung cancer (NSCLC), contributing to poor prognosis and immunotherapy resistance. The BCL-2 family pro-survival protein, MCL-1, is a critical controller of lymphoid Treg viability, yet its role in tumour-infiltrating Tregs remains poorly defined. Here we find that tumour-infiltrating effector Tregs in human NSCLC exhibit an activation-associated shift in BCL-2 family pro-survival protein expression typified by elevated MCL-1 expression. Pharmacological inhibition of MCL-1 with the BH3 mimetic S63845 induced moderate apoptotic cell death in both human and murine tumour-infiltrating Tregs, coincident with transient enhancement of CD8⁺ T cell activity, although these effects were not sustained long term. Combined MCL-1 inhibition and anti-PD1 immunotherapy further reduced tumour-infiltrating effector Treg abundance and influenced CD8⁺ T cell dynamics, indicating that targeting MCL-1 can transiently relieve Treg-mediated immunosuppression. These results establish MCL-1 as an important regulator for tumour-infiltrating Treg survival and highlights the potential of repurposing BH3 mimetics to modulate immune suppression in NSCLC.
- Open Access
- 1 December 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (12)
Mapping lung cancer ventilation dynamics using functional imaging and lung mechanics
In vivo models that replicate and reproduce human lung cancer and its response to therapy are necessary for the development of new therapeutic strategies and understanding drug resistance. Imaging lung tumors in live animals to monitor tumor growth and response to therapy is challenging owing to the location of the lungs and their constant movement during breathing. X-ray velocimetry (XV) is a novel functional lung imaging technique that maps regional lung expansion during breathing, providing spatial information on where ventilation changes occur. The aim of this pilot study was to use XV and flexiVent lung mechanics assessments to determine the effect of tumor growth on lung function in mice at 2 or 3 weeks post tumor induction and to evaluate the efficacy of these two tools. Histological analysis showed that tumor growth was not uniform between animals. At 3 weeks post tumor induction, some XV ventilation and flexiVent lung mechanics parameters were significantly different from baseline. Both techniques gave metrics that correlated with the tumor counts from the histology. In some mice, XV revealed localized regions with altered expansion rates.
- 1 December 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (12)
Open AccessMapping lung cancer ventilation dynamics using functional imaging and lung mechanics
In vivo models that replicate and reproduce human lung cancer and its response to therapy are necessary for the development of new therapeutic strategies and understanding drug resistance. Imaging lung tumors in live animals to monitor tumor growth and response to therapy is challenging owing to the location of the lungs and their constant movement during breathing. X-ray velocimetry (XV) is a novel functional lung imaging technique that maps regional lung expansion during breathing, providing spatial information on where ventilation changes occur. The aim of this pilot study was to use XV and flexiVent lung mechanics assessments to determine the effect of tumor growth on lung function in mice at 2 or 3 weeks post tumor induction and to evaluate the efficacy of these two tools. Histological analysis showed that tumor growth was not uniform between animals. At 3 weeks post tumor induction, some XV ventilation and flexiVent lung mechanics parameters were significantly different from baseline. Both techniques gave metrics that correlated with the tumor counts from the histology. In some mice, XV revealed localized regions with altered expansion rates.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 4. Analysis of immune cell populations in gPFS and loPFS samples.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 4. Analysis of immune cell populations in gPFS and loPFS samples.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 2. Representativeness of study participants
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 2. Representativeness of study participants
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 1. CAVATAK trial inclusion and exclusion criterias
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table 1. CAVATAK trial inclusion and exclusion criterias